| Contributors |
|
v | |
| Preface |
|
xxiii | |
| Chapter 1 Molecular Biomarkers in Primary Open-Angle Glaucoma: From Noninvasive to Invasive |
|
1 | (32) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 Introduction: What is a Biomarker? |
|
|
2 | (2) |
|
|
|
4 | (2) |
|
2.1 Proteomics Technologies for Biomarker Identification |
|
|
4 | (2) |
|
3 Noninvasive Biomarkers in Primary Open-Angle Glaucoma |
|
|
6 | (2) |
|
|
|
6 | (2) |
|
|
|
8 | (1) |
|
4 Minimally Invasive Biomarkers in Primary Open-Angle Glaucoma |
|
|
8 | (8) |
|
|
|
8 | (8) |
|
5 Invasive Biomarkers in Primary Open-Angle Glaucoma |
|
|
16 | (5) |
|
5.1 Aqueous Humor Biomarkers |
|
|
16 | (4) |
|
5.2 Vitreous Body Biomarkers |
|
|
20 | (1) |
|
5.3 Cerebrospinal Fluid Biomarkers |
|
|
21 | (1) |
|
6 Molecular Biomarkers in Clinical Practice: Is Translation Feasible? |
|
|
21 | (1) |
|
7 Summary and Conclusions |
|
|
22 | (1) |
|
|
|
23 | (10) |
| Chapter 2 Cerebrospinal Fluid Pressure in the Pathogenesis Of Glaucoma |
|
33 | (16) |
|
|
|
|
|
|
|
|
|
34 | (1) |
|
2 Anatomy and Dynamics of the Optic Nerve Head in Relationship to the Retrobulbar CSF Space |
|
|
34 | (2) |
|
|
|
36 | (1) |
|
4 Relationship Between CSFP and IOP and its Dynamics |
|
|
37 | (2) |
|
5 CSFP, TLPD, and TOP: Glaucomatous Optic Neuropathy |
|
|
39 | (2) |
|
|
|
41 | (1) |
|
7 Methods for Determining CSFP |
|
|
42 | (1) |
|
8 CSFP and Retinal and Choroidal Vein Pressure |
|
|
43 | (1) |
|
|
|
43 | (6) |
| Chapter 3 Links Among Glaucoma, Neurodegenerative, and Vascular Diseases of the Central Nervous System |
|
49 | (18) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50 | (2) |
|
|
|
52 | (4) |
|
|
|
56 | (1) |
|
|
|
57 | (1) |
|
5 Glaucoma and Cerebrovascular Diseases |
|
|
58 | (1) |
|
|
|
59 | (1) |
|
|
|
59 | (1) |
|
|
|
60 | (7) |
| Chapter 4 New Technologies for Measuring Intraocular Pressure |
|
67 | (14) |
|
|
|
Jose Maria Martinez-de-la-Casa |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
67 | (1) |
|
|
|
68 | (1) |
|
3 Dynamic Contour (Pascal) Tonometer |
|
|
69 | (1) |
|
|
|
70 | (3) |
|
|
|
70 | (1) |
|
|
|
71 | (1) |
|
|
|
72 | (1) |
|
|
|
73 | (1) |
|
6 Ocular Response Analyzer |
|
|
74 | (1) |
|
7 Transpalpebral Tonometers |
|
|
75 | (1) |
|
|
|
75 | (1) |
|
9 SENSIMED Triggerfish® Contact Lens Sensor |
|
|
76 | (1) |
|
|
|
77 | (4) |
| Chapter 5 Emerging Risk Factors for Glaucoma Onset and Progression |
|
81 | (22) |
|
|
|
|
|
|
|
|
|
81 | (1) |
|
|
|
82 | (9) |
|
2.1 IOP: A Causal Risk Factor |
|
|
82 | (4) |
|
|
|
86 | (1) |
|
2.3 Central Corneal Thickness |
|
|
87 | (1) |
|
|
|
87 | (1) |
|
|
|
88 | (1) |
|
|
|
89 | (1) |
|
|
|
90 | (1) |
|
|
|
91 | (2) |
|
3.1 Blood Pressure and Perfusion Pressure |
|
|
91 | (1) |
|
3.2 Cerebrospinal Fluid Pressure |
|
|
92 | (1) |
|
|
|
93 | (1) |
|
|
|
93 | (1) |
|
|
|
94 | (1) |
|
|
|
94 | (9) |
| Chapter 6 Strategies to Improve Early Diagnosis in Glaucoma |
|
103 | (32) |
|
|
|
|
|
|
|
|
|
1 Detecting Early Functional Change |
|
|
105 | (6) |
|
1.1 Standard Automated Perimetry |
|
|
105 | (3) |
|
1.2 Other Perimetric Devices |
|
|
108 | (3) |
|
2 Detecting Structural Change |
|
|
111 | (11) |
|
|
|
115 | (3) |
|
2.2 Longitudinal Structural Measurements |
|
|
118 | (1) |
|
2.3 What is the Earliest Detectable Change? |
|
|
119 | (3) |
|
|
|
122 | (1) |
|
3 Combining Information from Structural and Functional Tests |
|
|
122 | (1) |
|
|
|
123 | (1) |
|
|
|
124 | (1) |
|
|
|
124 | (11) |
| Chapter 7 How to Detect Progression in Glaucoma |
|
135 | (24) |
|
|
|
|
|
|
|
135 | (1) |
|
|
|
136 | (1) |
|
2.1 Event-Versus Trend-Based Analyses |
|
|
136 | (1) |
|
2.2 Global Versus Pointwise Analyses |
|
|
136 | (1) |
|
|
|
137 | (1) |
|
|
|
137 | (7) |
|
3.1 Standard Automated Perimetry |
|
|
137 | (6) |
|
3.2 Other Perimetric Techniques |
|
|
143 | (1) |
|
|
|
144 | (5) |
|
4.1 Confocal Scanning Laser Tomography |
|
|
144 | (3) |
|
4.2 Optical Coherence Tomography |
|
|
147 | (2) |
|
5 Combining Progression Techniques |
|
|
149 | (1) |
|
|
|
149 | (1) |
|
|
|
150 | (1) |
|
|
|
150 | (9) |
| Chapter 8 Brain Imaging in Glaucoma from Clinical Studies to Clinical Practice |
|
159 | (18) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
160 | (1) |
|
|
|
160 | (3) |
|
|
|
163 | (4) |
|
|
|
167 | (2) |
|
5 Voxel-Based Morphometry |
|
|
169 | (1) |
|
6 Magnetic Resonance Spectroscopy |
|
|
170 | (1) |
|
|
|
171 | (6) |
| Chapter 9 Primary Congenital Glaucoma |
|
177 | (14) |
|
|
|
|
|
|
|
|
|
178 | (1) |
|
|
|
178 | (1) |
|
|
|
179 | (1) |
|
|
|
180 | (1) |
|
|
|
181 | (1) |
|
|
|
181 | (3) |
|
|
|
182 | (2) |
|
|
|
184 | (1) |
|
|
|
185 | (1) |
|
|
|
185 | (6) |
| Chapter 10 New Findings in the Diagnosis and Treatment of Primary Angle-Closure Glaucoma |
|
191 | (22) |
|
|
|
|
|
|
|
|
|
|
|
191 | (1) |
|
|
|
192 | (1) |
|
|
|
192 | (2) |
|
|
|
194 | (2) |
|
|
|
196 | (2) |
|
|
|
197 | (1) |
|
5.2 Intermittent Angle Closure |
|
|
197 | (1) |
|
5.3 Chronic Angle Closure |
|
|
197 | (1) |
|
5.4 Narrow or Occludable AC Angle |
|
|
198 | (1) |
|
|
|
198 | (1) |
|
|
|
198 | (1) |
|
|
|
198 | (1) |
|
6.3 Anterior Segment Imaging |
|
|
198 | (1) |
|
|
|
199 | (4) |
|
|
|
199 | (1) |
|
|
|
200 | (1) |
|
7.3 Argon Laser Peripheral Iridoplasty |
|
|
200 | (1) |
|
|
|
201 | (1) |
|
|
|
202 | (1) |
|
|
|
202 | (1) |
|
7.7 Glaucoma Drainage Implant |
|
|
202 | (1) |
|
|
|
203 | (1) |
|
|
|
203 | (1) |
|
|
|
204 | (2) |
|
|
|
204 | (1) |
|
9.2 Lens-Induced Glaucoma |
|
|
205 | (1) |
|
|
|
205 | (1) |
|
9.4 Choroidal Effusion and Ciliary Body Rotation |
|
|
206 | (1) |
|
|
|
206 | (7) |
| Chapter 11 Advance in the Pathogenesis and Treatment of Normal-Tension Glaucoma |
|
213 | (20) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
214 | (1) |
|
2 Advance in the Pathogenesis of Normal-Tension Glaucoma |
|
|
214 | (6) |
|
2.1 Vascular and Mechanical Factors |
|
|
214 | (3) |
|
2.2 Oxidative Stress, Neurotoxicity, and Autoimmunity |
|
|
217 | (1) |
|
|
|
218 | (2) |
|
3 Advance in the Treatment of Normal-Tension Glaucoma |
|
|
220 | (4) |
|
|
|
221 | (2) |
|
3.2 Neuroprotective and Vasoactive Strategies |
|
|
223 | (1) |
|
|
|
224 | (1) |
|
|
|
224 | (9) |
| Chapter 12 Exfoliative Glaucoma: New Evidence in the Pathogenesis and Treatment |
|
233 | (10) |
|
|
|
|
|
|
|
233 | (1) |
|
2 Pathophysiology and Genetic Features |
|
|
234 | (2) |
|
3 Geographic and Epidemiologic Features |
|
|
236 | (1) |
|
4 Clinical Outcome and Treatment |
|
|
237 | (2) |
|
|
|
237 | (1) |
|
|
|
238 | (1) |
|
|
|
238 | (1) |
|
|
|
239 | (1) |
|
|
|
239 | (4) |
| Chapter 13 Uveitis and Glaucoma: New Insights in the Pathogenesis and Treatment |
|
243 | (28) |
|
|
|
|
|
|
|
|
|
243 | (1) |
|
|
|
244 | (8) |
|
|
|
244 | (3) |
|
|
|
247 | (2) |
|
|
|
249 | (3) |
|
|
|
252 | (7) |
|
|
|
252 | (1) |
|
|
|
253 | (1) |
|
3.3 Specific Treatment for Angle Closure |
|
|
254 | (2) |
|
|
|
256 | (2) |
|
3.5 Glaucoma Drainage Devices |
|
|
258 | (1) |
|
|
|
258 | (1) |
|
3.7 Other Surgical Procedures |
|
|
259 | (1) |
|
|
|
259 | (1) |
|
|
|
260 | (11) |
| Chapter 14 Glaucoma Risks in Advanced Corneal Surgery |
|
271 | (26) |
|
|
|
|
|
1 Mechanism of Steroid-Induced Glaucoma |
|
|
273 | (1) |
|
2 Lamellar and Penetrating Keratoplasty |
|
|
274 | (3) |
|
3 Glaucoma Risk and Penetrating Keratoplasty |
|
|
277 | (1) |
|
4 Glaucoma Risk and Deep Anterior Lamellar Keratoplasty |
|
|
278 | (1) |
|
5 Glaucoma Risk and Descemet Stripping-Automated Endothelial Keratoplasty |
|
|
279 | (2) |
|
6 Glaucoma Risk and Descemet Membrane Endothelial Keratoplasty |
|
|
281 | (1) |
|
7 Post-Corneal Graft Glaucoma Treatment |
|
|
282 | (1) |
|
|
|
282 | (1) |
|
|
|
282 | (1) |
|
|
|
283 | (2) |
|
9 Laser-Assisted In Situ Keratomileusis—Interface Fluid Syndrome |
|
|
285 | (1) |
|
10 Urrets-Zavalia Syndrome |
|
|
286 | (1) |
|
|
|
287 | (1) |
|
|
|
288 | (9) |
| Chapter 15 Twenty-Four Hour Efficacy of Glaucoma Medications |
|
297 | (22) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
298 | (3) |
|
2 24-Hour Efficacy of Monotherapies |
|
|
301 | (6) |
|
|
|
301 | (4) |
|
|
|
305 | (1) |
|
2.3 Topical Carbonic Anhydrase Inhibitors |
|
|
306 | (1) |
|
|
|
306 | (1) |
|
3 24-Hour Efficacy of Combined Therapy |
|
|
307 | (1) |
|
4 Combinations of Prostaglandin Analogues with β-Blockers |
|
|
308 | (1) |
|
4.1 Latanoprost and Timolol |
|
|
308 | (1) |
|
4.2 Travoprost and Timolol |
|
|
308 | (1) |
|
4.3 Bimatoprost and Timolol |
|
|
309 | (1) |
|
5 Combinations of Carbonic Anhydrase Inhibitors with β-Blockers |
|
|
309 | (2) |
|
5.1 Dorzolamide and Timolol |
|
|
309 | (1) |
|
5.2 Brinzolamide and Timolol |
|
|
310 | (1) |
|
6 Combinations of Carbonic Anhydrase Inhibitors with a Prostaglandin Analogue |
|
|
311 | (1) |
|
6.1 Combination of Dorzolamide or Brinzolamide and Latanoprost |
|
|
311 | (1) |
|
7 Combination of an Alpha-2 Agonist and a β-Blocker |
|
|
311 | (1) |
|
7.1 Combination of Brimonidine and Timolol |
|
|
311 | (1) |
|
8 Combination of an Alpha-2 Agonist and a Carbonic Anhydrase Inhibitor |
|
|
312 | (1) |
|
|
|
312 | (7) |
| Chapter 16 Modulation of Wound Healing in Glaucoma Surgery |
|
319 | (22) |
|
|
|
|
|
|
|
|
|
|
|
|
|
319 | (1) |
|
|
|
320 | (1) |
|
3 Modulation of Wound Healing: Clinical Practice |
|
|
321 | (2) |
|
3.1 Anti-Inflammatory Agents: Steroids and NSAIDs |
|
|
322 | (1) |
|
3.2 Antimitotics: MMC and 5-FU |
|
|
323 | (1) |
|
4 New Methods and Upcoming Trends in Wound Healing |
|
|
323 | (8) |
|
4.1 Cytoskeletal Regulators |
|
|
324 | (3) |
|
4.2 Growth Factors, Cytokines, and Proteinases |
|
|
327 | (4) |
|
4.3 Amniotic Membrane Transplantation |
|
|
331 | (1) |
|
|
|
331 | (1) |
|
|
|
332 | (9) |
| Chapter 17 Emerging Surgical Therapy in the Treatment of Glaucoma |
|
341 | (18) |
|
|
|
|
|
|
|
|
|
|
|
341 | (2) |
|
2 Ab Externo and Ab Interno Procedures |
|
|
343 | (1) |
|
3 Enhancing Outflow Procedures |
|
|
344 | (8) |
|
3.1 Ab Externo Filtering Procedures |
|
|
344 | (3) |
|
3.2 Ab Interno Filtering Procedures |
|
|
347 | (1) |
|
3.3 Ab Externo Procedures Restoring the Natural Path way |
|
|
348 | (1) |
|
3.4 Ab Interno Procedures Restoring the Natural Pathway |
|
|
349 | (2) |
|
3.5 Ab Externo Procedures Diverting Aqueous Humor in the Suprachoroidal Space |
|
|
351 | (1) |
|
3.6 Ab Interno Procedures Diverting Aqueous Humor in the Suprachoroidal Space |
|
|
352 | (1) |
|
4 Reducing Aqueous Production Procedures |
|
|
352 | (2) |
|
|
|
354 | (1) |
|
|
|
355 | (4) |
| Chapter 18 Visual Disability and Quality of Life in Glaucoma Patients |
|
359 | (16) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
359 | (1) |
|
2 Methods for Correlating Visual Disability and Quality of Life |
|
|
360 | (4) |
|
3 Disabilities in Glaucoma |
|
|
364 | (4) |
|
4 Rehabilitation in Glaucoma |
|
|
368 | (1) |
|
|
|
368 | (1) |
|
|
|
369 | (6) |
| Index |
|
375 | (10) |
| Other Volumes In Progress In Brain Research |
|
385 | |
Lisainfo e-raamatute kohta